Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation

Zordoky, 2010, Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases, Pharmacol. Ther., 125, 446, 10.1016/j.pharmthera.2009.12.002 Konkel, 2011, Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids, Biochim. Biophys. Acta., 1814, 210, 10.1016/j.bbapap.2010.09.009 Devos, 2010, Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation, Prostaglandins Leukot. Essent. Fatty Acids., 83, 105, 10.1016/j.plefa.2010.06.005 Miyata, 2005, Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system, J. Smooth Muscle Res., 41, 175, 10.1540/jsmr.41.175 Wu, 2011, The role of 20-HETE in androgen-mediated hypertension, Prostaglandins Other Lipid Mediat., 96, 45, 10.1016/j.prostaglandins.2011.06.006 Liu, 2010, Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events, Proc. Natl. Acad. Sci. USA., 107, 17017, 10.1073/pnas.1011278107 Baines, 2005, 20-HETE-mediated vasoconstriction by hemoglobin-O2 carrier in Sprague-Dawley but not Wistar rats, J. Appl. Physiol., 98, 772, 10.1152/japplphysiol.00638.2004 Vasudevan, 2012, Testosterone-dependent increase in blood pressure is mediated by elevated Cyp4A expression in fructose-fed rats, Mol. Cell. Biochem., 359, 409, 10.1007/s11010-011-1035-7 Ward, 2004, Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans, Circulation., 110, 438, 10.1161/01.CIR.0000136808.72912.D9 Mayer, 2005, Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy, Hypertension., 46, 766, 10.1161/01.HYP.0000182658.04299.15 Liu, 2008, Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension, J. Am. Soc. Nephrol., 19, 714, 10.1681/ASN.2007060713 Williams, 2010, 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension, J. Cardiovasc. Pharmacol., 56, 336, 10.1097/FJC.0b013e3181f04b1c Watzer, 2000, Determination of free and glucuronide conjugated 20-hydroxyarachidonic acid (20-HETE) in urine by gas chromatography/negative ion chemical ionization mass spectrometry, Prostaglandins Leukot. Essent. Fatty Acids., 62, 175, 10.1054/plef.2000.0138 Ward, 2005, Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects, Free Radic. Biol. Med., 38, 1032, 10.1016/j.freeradbiomed.2004.12.024 Pat Kunert, 2011, 20-Hydroxyeicosatetraenoic acid, endothelial dysfunction and hypertension, Med. Glas. (Zenica)., 8, 170 Williams, 2007, Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis, Hypertension., 49, 687, 10.1161/01.HYP.0000255753.89363.47 Lohr, 1998, Renal drug metabolism, Pharmacol. Rev., 50, 107 Tukey, 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease, Annu. Rev. Pharmacol. Toxicol., 40, 581, 10.1146/annurev.pharmtox.40.1.581 Court, 2010, Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system, Drug Metab. Rev., 42, 209, 10.3109/03602530903209288 Guillemette, 2003, Pharmacogenomics of human UDP-glucuronosyltransferase enzymes, Pharmacogenomics J., 3, 136, 10.1038/sj.tpj.6500171 Turgeon, 2003, Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases, J. Lipid Res., 44, 1182, 10.1194/jlr.M300010-JLR200 Lee, 2009, Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans, Drug Metab. Dispos., 37, 1464, 10.1124/dmd.108.022368 Seo, 2010, Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7, Drug Metab. Dispos., 38, 2007, 10.1124/dmd.110.035295 Little, 2004, Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases, J. Lipid Res., 45, 1694, 10.1194/jlr.M400103-JLR200 King, 2001, Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac, Toxicol. Sci., 61, 49, 10.1093/toxsci/61.1.49 Chen, 2006, Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population, Drug Metab. Dispos., 34, 1462, 10.1124/dmd.106.009761 Hwang, 2010, Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population, Drug Metab. Pharmacokinet., 25, 398, 10.2133/dmpk.DMPK-10-SC-021 Yea, 2008, Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population, Ther. Drug Monit., 30, 23, 10.1097/FTD.0b013e3181633824 Saito, 2009, Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese, Drug Metab. Dispos., 37, 272, 10.1124/dmd.108.024208 Girard, 2006, The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver, Drug Metab. Dispos., 34, 1220, 10.1124/dmd.106.009787 Sacerdoti, 1997, Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE, J. Clin. Invest., 100, 1264, 10.1172/JCI119640 Debinski, 1996, UDP glucuronosyltransferase in the cirrhotic rat liver, J. Gastroenterol. Hepatol., 11, 373, 10.1111/j.1440-1746.1996.tb01386.x Yamanaka, 2004, A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity, Pharmacogenetics., 14, 329, 10.1097/00008571-200405000-00008 Thibaudeau, 2006, Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone, Cancer Res., 66, 125, 10.1158/0008-5472.CAN-05-2857 Parmar, 2011, Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer, Breast Cancer Res., 13, R57, 10.1186/bcr2894 Daly, 2007, Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes, Gastroenterology., 132, 272, 10.1053/j.gastro.2006.11.023 Duguay, 2004, A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity, Clin. Pharmacol. Ther., 75, 223, 10.1016/j.clpt.2003.10.006